For which of the following conditions is the use of ribavirin (antiviral medication) not indicated: (a) West Nile virus, (b) influenza virus, (c) Hepatitis B virus (HBV) infection, (d) Hepatitis C virus (HCV) infection, (e) Lassa, adenovirus, Respiratory Syncytial Virus (RSV), bronchiolitis, or (f) Pneumocystis carinii pneumonia (PCP)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 2, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Ribavirin is Not Indicated for West Nile Virus

Based on the evidence, ribavirin is not indicated for West Nile virus (option a), as it has shown potential harmful effects in clinical trials according to the Infectious Diseases Society of America. 1

Analysis of Indications for Ribavirin

Ribavirin has specific approved indications and several off-label uses based on clinical evidence:

Approved Indications:

  • Hepatitis C virus (HCV) infection: Ribavirin is recommended in combination therapy for chronic HCV infection 2, 3
  • Respiratory Syncytial Virus (RSV): FDA-approved for treatment of severe lower respiratory tract infections due to RSV, particularly in hospitalized infants and young children 4, 2
  • RSV bronchiolitis: May be considered in highly selected situations with severe disease or in immunocompromised patients 1

Other Evidence-Supported Uses:

  • Lassa fever: Ribavirin has demonstrated efficacy for treatment and post-exposure prophylaxis 2
  • Crimean-Congo hemorrhagic fever: Recommended with specific dosing regimen 1
  • Hematopoietic stem cell transplantation patients with RSV: Can be administered as aerosolized or systemic therapy 2

Not Indicated For:

  • West Nile virus (WNV): Ribavirin is specifically not recommended due to potential harmful effects in clinical trials 1, 5
  • Hepatitis B virus (HBV): Not indicated for HBV infection 1, 6
  • Pneumocystis carinii pneumonia (PCP): Not recommended; other agents like trimethoprim-sulfamethoxazole are preferred 1

Evaluation of Each Option

  1. West Nile virus (a): Ribavirin is NOT indicated and may have harmful effects 1

  2. Influenza virus (b): While ribavirin has shown in vitro activity against influenza, it is not the preferred treatment. Neuraminidase inhibitors like oseltamivir and zanamivir are the recommended treatments 2, 7

  3. Hepatitis B virus infection (c): Ribavirin is NOT indicated for HBV infection 1, 6

  4. Hepatitis C virus infection (d): Ribavirin IS indicated as part of combination therapy for HCV 2, 3

  5. Lassa, adenovirus, RSV, bronchiolitis (e): Ribavirin IS indicated for these conditions:

    • Lassa fever: Demonstrated efficacy 2
    • RSV: FDA-approved indication 4
    • Bronchiolitis due to RSV: Indicated in severe cases 1
    • Adenovirus: Has shown activity against adenovirus 4
  6. Pneumocystis carinii pneumonia (f): Ribavirin is NOT recommended for PCP treatment 1

Important Considerations for Ribavirin Use

  • Administration routes: Can be given orally, intravenously, or via nebulizer depending on indication 4
  • Adverse effects: Common side effects include hemolytic anemia, thrombocytosis, and potential teratogenicity 1, 4
  • Contraindications: Relatively contraindicated in pregnancy, severe anemia, hemoglobinopathy, coronary artery disease, renal failure, and decompensated liver disease 1
  • Monitoring: Patients should be monitored for hemoglobin and hematocrit levels during treatment 1

Therefore, among the options provided, West Nile virus (option a) is the condition for which ribavirin is not indicated.

References

Guideline

Antiviral Therapy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Use of Ribavirin for Hepatitis C Treatment in the Modern Direct-acting Antiviral Era.

Journal of clinical and translational hepatology, 2018

Research

Ribavirin--current status of a broad spectrum antiviral agent.

Expert opinion on pharmacotherapy, 2001

Research

Antiviral drugs: current state of the art.

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2001

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.